Opinion

Video

Role of Androgen Deprivation Therapy in Advanced Prostate Cancer

Author(s):

Nilay Gandhi, MD

In the first interview of the series, Nilay Gandhi, MD, provides an overview of advanced/metastatic prostate cancer and the role of androgen deprivation therapy in treating patients.

Current Time 0:00
Duration 6:23
Loaded: 2.57%
Stream Type LIVE
Remaining Time 6:23
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected
    Related Videos
    Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
    Study findings highlight gender gaps in oncology authorship and citation
    Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
    Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
    Jim Hu, MD, on urinary continence recovery across RARP techniques
    Jim Hu, MD, on urinary continence recovery across RARP techniques
    1 expert in this video
    Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC
    1 expert in this video
    Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
    Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
    Special Report: Tips for PCPs on evaluating prostate cancer risk
    Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
    Special Report: Tailoring prostate cancer care for older adults
    Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
    Special Report: New strategies emerge for metastatic prostate cancer
    Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
    Special Report: Biden’s prostate cancer diagnosis renews focus on screening guidelines
    De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment options
    De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment options
    Related Content
    A. Oliver Sartor, MD
    June 2nd 2025

    Long-term data support radium-223 safety in mCRPC

    Benjamin P. Saylor
    “Prior taxanes did not increase reported hematological adverse events during treatment with Ra-223,” the investigators reported.
    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
    April 27th 2025

    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

    Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
    Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
    Conceptual image for prostate cancer treatment | Image Credit: © Dr_Microbe - stock.adobe.com
    May 30th 2025

    PEACE-3 data for radium-223/enzalutamide published in Annals of Oncology

    Benjamin P. Saylor
    The addition of Ra223 to enzalutamide was associated with a 31% reduction in the risk of progression or death compared with enzalutamide alone.
    Dr. Murphy on increasing diversity in cancer clinical trials
    February 29th 2024

    Dr. Murphy on increasing diversity in cancer clinical trials

    Urology Times staff
    In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
    ORIC-944 shows promise in combination with AR inhibitors in mCRPC
    May 30th 2025

    ORIC-944 shows promise in combination with AR inhibitors in mCRPC

    Hannah Clarke
    Overall, 59% of patients achieved at least a 50% decline in PSA level.
    FDA awards Regenerative Medicine Advanced Therapy Designation to CAN-2409 for prostate cancer
    May 29th 2025

    FDA awards Regenerative Medicine Advanced Therapy Designation to CAN-2409 for prostate cancer

    Hannah Clarke
    The company plans to submit a Biologics License Application to the FDA at the end of 2026.
    © 2025 MJH Life Sciences

    All rights reserved.